-
New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)
Wednesday, January 29, 2014 - 12:44pm | 807Read More...Among the leading biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) saw the most significant upswings between the December 31 and January 15 settlement dates. Gilead Sciences, Pharmacyclics and Regeneron...
-
Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, CELG, DNDN)
Saturday, January 11, 2014 - 12:46pm | 778Read More...The number of shares sold short in leading biotech and emerging pharmaceutical companies mostly declined between the December 13 and December 31 settlement dates. BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) led that trend. Short sellers also shied...
-
Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, GILD, PCYC)
Thursday, December 26, 2013 - 2:26pm | 748Read More...Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Amgen (NASDAQ: AMGN), Gilead Sciences (NASDAQ: GILD) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages between the November 29 and December 13 settlement dates. Medivation saw its short...
-
Biogen Idec, Pharmacyclics See Surges In Short Interest (BIIB, CELG, PCYC)
Wednesday, December 11, 2013 - 2:47pm | 807Read More...Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Biogen Idec (NASDAQ: BIIB), Celgene (NASDAQ: CELG) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages in late November. Gilead Sciences, Regeneron Pharmaceuticals, Seattle Genetics and...
-
Gilead Sciences Leads In Rising Short Interest Among Biotechs
Tuesday, November 12, 2013 - 5:41pm | 1296Read More...Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), BioMarin Pharmaceutical (NASDAQ: BMRN) and Gilead Sciences (NASDAQ: GILD) grew by the largest percentages in late October. Biogen Idec (NASDAQ: BIIB), Illumina...
-
Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)
Friday, October 25, 2013 - 3:36pm | 924Read More...Among leading biotech and emerging pharmaceutical companies, short sellers retreated from Biogen Idec (NASDAQ: BIIB) by the largest percentage in early October. Amgen (NASDAQ: AMGN), Illumina (NASDAQ: ILMN), Regeneron Pharmaceuticals (NASDAQ: REGN) and Seattle Genetics (NASDAQ: SGEN) saw short...
-
Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)
Friday, October 11, 2013 - 2:33pm | 901Read More...Among leading biotech and emerging pharmaceutical companies, short sellers moved on Amgen (NASDAQ: AMGN), Pharmacyclics (NASDAQ: PCYC) and Vertex Pharmaceuticals (NASDAQ: VRTX) the most strongly in late September. The number of shares sold short in Dendreon (NASDAQ: DNDN) and Biogen Idec (NASDAQ:...
-
BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)
Wednesday, September 25, 2013 - 12:52pm | 897Read More...Among leading biotech and emerging pharmaceutical companies, short sellers moved on BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Regeneron Pharmaceuticals (NASDAQ: REGN) the most between the August 30 and September 13 settlement dates. The number of shares sold short in...
-
Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)
Saturday, September 14, 2013 - 11:47am | 910Read More...Declining short interest in Alexion Pharmaceuticals (NASDAQ: ALXN) and Pharmacyclics (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical companies between the August 15 and August 30 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Biogen...
-
BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November
Sunday, December 2, 2012 - 9:29pm | 617Read More...Here is a quick look at some of the top-performing health care sector stocks in the past month. These companies all have a market cap of more than $500 million, and their share prices are more than 20 percent higher than 30 days ago. BioMarin Pharmaceutical (NASDAQ: BMRN) in early November...
-
Dendreon, Pharmacyclics and Other Biotech Takeover Targets
Tuesday, July 10, 2012 - 2:07pm | 806Read More...M&A in the biotech and pharmaceutical industries continues. Bristol-Myers Squibb (NYSE: BMY) just announced it has agreed to acquire Amylin Pharmaceuticals (NASDAQ: AMLN) for $5.3 billion. And Human Genome Sciences (NASDAQ: HGSI) has opened itself up to bidders, including GlaxoSmithKline (NYSE...
-
Wells Fargo Resumes Coverage On BioMarin With $23-$28 Valuation Range
Friday, December 10, 2010 - 11:18am | 84Read More...Wells Fargo is resuming coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a change in analyst, a Market Perform rating on the shares, and a $23-$28 valuation range. “We believe BMRN's attractive attributes, including steady revenues from Orphan agents without competitors or patent cliffs...
